JP6059735B2 - 脳卒中診断のためのNT−proANP及びNT−proBNP - Google Patents

脳卒中診断のためのNT−proANP及びNT−proBNP Download PDF

Info

Publication number
JP6059735B2
JP6059735B2 JP2014543882A JP2014543882A JP6059735B2 JP 6059735 B2 JP6059735 B2 JP 6059735B2 JP 2014543882 A JP2014543882 A JP 2014543882A JP 2014543882 A JP2014543882 A JP 2014543882A JP 6059735 B2 JP6059735 B2 JP 6059735B2
Authority
JP
Japan
Prior art keywords
subject
tia
amount
sample
proanp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014543882A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504519A5 (enExample
JP2015504519A (ja
Inventor
ヘス,ゲオルク
ホルシュ,アンドレア
ズドゥネック,ディートマー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2015504519A publication Critical patent/JP2015504519A/ja
Publication of JP2015504519A5 publication Critical patent/JP2015504519A5/ja
Application granted granted Critical
Publication of JP6059735B2 publication Critical patent/JP6059735B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2871Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014543882A 2011-12-01 2012-11-29 脳卒中診断のためのNT−proANP及びNT−proBNP Active JP6059735B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11191579.9 2011-12-01
EP11191579 2011-12-01
PCT/EP2012/073897 WO2013079567A2 (en) 2011-12-01 2012-11-29 Nt-proanp and nt-probnp for the diagnosis of stroke

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016239317A Division JP6441885B2 (ja) 2011-12-01 2016-12-09 脳卒中診断のためのNT−proANP及びNT−proBNP

Publications (3)

Publication Number Publication Date
JP2015504519A JP2015504519A (ja) 2015-02-12
JP2015504519A5 JP2015504519A5 (enExample) 2016-10-20
JP6059735B2 true JP6059735B2 (ja) 2017-01-11

Family

ID=47278813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543882A Active JP6059735B2 (ja) 2011-12-01 2012-11-29 脳卒中診断のためのNT−proANP及びNT−proBNP
JP2016239317A Active JP6441885B2 (ja) 2011-12-01 2016-12-09 脳卒中診断のためのNT−proANP及びNT−proBNP

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016239317A Active JP6441885B2 (ja) 2011-12-01 2016-12-09 脳卒中診断のためのNT−proANP及びNT−proBNP

Country Status (7)

Country Link
US (2) US10732188B2 (enExample)
EP (2) EP3290924B1 (enExample)
JP (2) JP6059735B2 (enExample)
CN (2) CN107064516B (enExample)
CA (2) CA2856461C (enExample)
ES (2) ES2899923T3 (enExample)
WO (1) WO2013079567A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016056664A1 (ja) * 2014-10-10 2016-04-14 松森 昭 心不全患者の検出方法、心疾患の識別方法、心不全の検査試薬、心不全の検査キット、心不全を検出するための装置及び心不全を検出するためのプログラム
BR112021001798A2 (pt) * 2018-07-31 2021-04-27 F. Hoffmann-La Roche Ag métodos para avaliar a fibrilação atrial, para diagnosticar insuficiência cardíaca, para auxiliar na avaliação da fibrilação atrial, para prever o risco de acidente vascular cerebral e para aprimorar a precisão da previsão, usos e kit
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US12322100B2 (en) 2018-12-11 2025-06-03 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity
US12400762B2 (en) 2018-12-11 2025-08-26 Eko.Ai Pte. Ltd. Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
JP7698310B2 (ja) * 2019-05-16 2025-06-25 フンダシオ オスピタル ウニベルシタリ バル デブロン-インスティテュート デ レセルカ 再灌流療法のために患者を選択する方法
JP2021173559A (ja) 2020-04-21 2021-11-01 株式会社デンソー 物理量計測装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
WO2003016910A1 (en) 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US7632647B2 (en) 2001-04-13 2009-12-15 Biosite Incorporated Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes
DE60233301D1 (de) 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
WO2004059293A2 (en) * 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7517951B2 (en) * 2002-12-24 2009-04-14 Nitto Boseki Co., Ltd. Marker proteins for diagnosing liver disease and method of diagnosing liver disease using the same
US20050181386A1 (en) * 2003-09-23 2005-08-18 Cornelius Diamond Diagnostic markers of cardiovascular illness and methods of use thereof
EP1582597A1 (en) 2004-03-29 2005-10-05 Aventis Pharma Deutschland GmbH Method of diagnosis of a predisposition to develop thrombotic disease and its uses
US20060166303A1 (en) * 2005-01-24 2006-07-27 Eberhard Spanuth Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs
WO2006077265A1 (en) 2005-01-24 2006-07-27 F. Hoffmann-La Roche Ag The use of bnp-type peptides and anp-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload
JP4828550B2 (ja) * 2005-02-17 2011-11-30 エフ.ホフマン−ラ ロシュ アーゲー 心機能障害を診断するためのNT−proANP/NT−proBNP比の使用
EP1731910A1 (en) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Use of NT-proANP and NT-proBNP for diagnosing cardiac diseases
DE102005048899A1 (de) * 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Diagnose thromboembolischer Erkrankungen und koronarer Herzerkrankungen
DE602006014798D1 (de) 2006-03-24 2010-07-22 Roche Diagnostics Gmbh Vorrichtung und Verfahren zur Unterscheidung zwischen akuter und chronischer Myokardial-Nekrose bei symptomatischen Patienten
EP1882945A1 (en) * 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath
DE602006010705D1 (de) * 2006-09-15 2010-01-07 Roche Diagnostics Gmbh Biochemische Marker für akute Lungenembolie
WO2009047285A1 (en) 2007-10-10 2009-04-16 Roche Diagnostics Gmbh Natriuretic peptide/troponin ratio for the assessment of preexisting myocardial dysfunction in patients with acute coronary syndrome
EP2356450B1 (en) * 2008-10-24 2019-02-06 B.R.A.H.M.S GmbH Prognosis and risk assessment in stroke patients by determining the level of marker peptides
AU2009339152B2 (en) * 2009-01-30 2015-11-19 Bio-Rad Europe Gmbh Method for the in vitro diagnosis of stroke
EP2466311A1 (en) 2010-12-17 2012-06-20 Roche Diagnostics GmbH sFlt1 in patients with ischemic stroke

Also Published As

Publication number Publication date
CN104094121A (zh) 2014-10-08
CA3081979A1 (en) 2013-06-06
EP2786154B1 (en) 2017-11-01
HK1201327A1 (en) 2015-08-28
CN104094121B (zh) 2016-10-26
US20200333360A1 (en) 2020-10-22
WO2013079567A3 (en) 2013-08-29
WO2013079567A2 (en) 2013-06-06
EP2786154A2 (en) 2014-10-08
US20140274793A1 (en) 2014-09-18
EP3290924B1 (en) 2021-10-13
JP6441885B2 (ja) 2018-12-19
CN107064516A (zh) 2017-08-18
EP3290924A1 (en) 2018-03-07
ES2899923T3 (es) 2022-03-15
US10732188B2 (en) 2020-08-04
ES2656082T3 (es) 2018-02-23
JP2017075959A (ja) 2017-04-20
JP2015504519A (ja) 2015-02-12
CA3081979C (en) 2023-07-11
CA2856461A1 (en) 2013-06-06
CN107064516B (zh) 2019-08-02
CA2856461C (en) 2020-08-18

Similar Documents

Publication Publication Date Title
JP6441885B2 (ja) 脳卒中診断のためのNT−proANP及びNT−proBNP
JP6654668B2 (ja) 発作性心房細動のbnp型ペプチドに基づく診断をするためのデータを提供する方法
US11047865B2 (en) Troponin and BNP based diagnosis of risk patients and cause of stroke
JP2015537208A (ja) 心不全リスクの予測改善のためのバイオマーカー
HK1241021B (zh) 用於诊断中风的nt-原anp和nt-原bnp
WO2013017690A2 (en) Troponin based rule in and rule out algorithm of myocardial infarction
HK1201327B (en) Nt-proanp and nt-probnp for the diagnosis of stroke
HK1241021A1 (en) Nt-proanp and nt-probnp for the diagnosis of stroke
HK1196158B (en) Troponin and bnp based diagnosis of risk patients and cause of stroke
HK1224745A1 (en) Troponin and bnp based diagnosis of risk patients and cause of stroke
HK1224745B (zh) 风险患者和中风原因的基於肌钙蛋白和bnp的诊断

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161209

R150 Certificate of patent or registration of utility model

Ref document number: 6059735

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250